Betegapolo Irgalmasrend Budai Irgalmasrendi Korhaz
- Address
- Arpad Fejedelem Utja 7, 1023 Budapest, Hungary
Betegapolo Irgalmasrend Budai Irgalmasrendi Korhaz - Rheumatology and Cardiovascular Research Center
Betegapolo Irgalmasrend Budai Irgalmasrendi Korhaz is a prominent clinical research institution specializing in advanced therapeutic interventions for inflammatory arthropathies and cardiovascular diseases. The center demonstrates particular expertise in evaluating novel biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for various rheumatologic conditions, with extensive experience in both biologic-naïve and biologic-experienced patient populations.
- Psoriatic arthritis research across multiple treatment lines, including studies of IL-23, IL-17, and JAK inhibitors in patients with active disease manifestations and axial involvement
- Rheumatoid arthritis clinical trials evaluating innovative biologics and JAK inhibitors in moderate to severe disease, including methotrexate-inadequate responders
- Heart failure and cardiovascular disease investigations, including myocardial infarction interventions, iron supplementation therapy, and novel therapeutic approaches for chronic heart failure
- Rare inflammatory conditions including eosinophilic granulomatosis with polyangiitis (EGPA) and refractory angina associated with coronary artery disease
The center's comprehensive approach encompasses both Phase 2 and Phase 3 clinical trials, with a strong focus on comparative effectiveness studies and long-term extension protocols. Their research portfolio includes evaluation of cardiovascular outcomes, structural progression prevention in arthritis, and quality of life improvements across multiple therapeutic areas, positioning them as a key contributor to evidence-based medicine in both rheumatology and cardiology.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 8 therapeutic areas and 15 of 36 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
- 1Janssen Cilag International2active
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International8trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Betegapolo Irgalmasrend Budai Irgalmasrendi Korhaz
lock Showing 1 of 34 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 1 First-in-Human Study to Evaluate the Safety and Pharmacokinetics of SAR447754 in Healthy Adults and Adults with Moderate-to-Severe Atopic Dermatitis | Sanofi-Aventis Recherche & Developpement | Phase I | Recruiting | Feb 2026 | — |
IMP list
lock Showing 1 of 36 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Sonelokimab | 3 | Unknown | 2025-03-25 | 2025-03-25 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.